Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer Immunology, Immunotherapy
Published in: Cancer Immunology, Immunotherapy 2/2011

Open Access 01-02-2011 | Original Article

CDR2 antigen and Yo antibodies

Authors: Cecilie Totland, Nina K. Aarskog, Tilo W. Eichler, Mette Haugen, Jane K. Nøstbakken, Sissel E. Monstad, Helga B. Salvesen, Sverre Mørk, Bjørn I. Haukanes, Christian A. Vedeler

Published in: Cancer Immunology, Immunotherapy | Issue 2/2011

Login to get access

Abstract

Paraneoplastic cerebellar degeneration (PCD) is often associated with Yo antibodies that are directed against human cerebellar degeneration-related protein 2 (CDR2). Such antibodies may also be found in ovarian cancer patients without PCD. We studied if there was an association between Yo antibody production and differences in CDR2 cDNA sequence, mRNA or CDR2 expression in ovarian cancers. We found similar CDR2 cDNA sequence, mRNA and protein levels in primary ovarian cancers, with or without associated Yo antibodies. CDR2 was also present in other cancers, as well as in normal ovary tissue. The results suggest that Yo antibodies are not only related to the expression of CDR2 alone, but also to immune dysregulation.
Literature
1.
Darnell RB, Posner JB (2003) Paraneoplastic syndromes involving the nervous system. N Engl J Med 349:1543–1554CrossRefPubMed
2.
Storstein A, Vedeler CA (2007) Paraneoplastic neurological syndromes and onconeural antibodies: clinical and immunological aspects. Adv Clin Chem 44:143–185CrossRefPubMed
3.
Corradi JP, Yang C, Darnell JC, Dalmau J, Darnell RB (1997) A post-transcriptional regulatory mechanism restricts expression of the paraneoplastic cerebellar degeneration antigen cdr2 to immune privileged tissues. J Neurosci 17:1406–1415PubMed
4.
Darnell JC, Albert ML, Darnell RB (2000) Cdr2, a target antigen of naturally occuring human tumor immunity, is widely expressed in gynecological tumors. Cancer Res 60:2136–2139PubMed
5.
Okano HJ, Park WY, Corradi JP, Darnell RB (1999) The cytoplasmic Purkinje onconeural antigen cdr2 down-regulates c-Myc function: implications for neuronal and tumor cell survival. Genes Dev 13:2087–2097CrossRefPubMed
6.
Sakai K, Shirakawa T, Li Y, Kitagawa Y, Hirose G (2002) Interaction of a paraneoplastic cerebellar degeneration-associated neuronal protein with the nuclear helix-loop-helix leucine zipper protein MRG X. Mol Cell Neurosci 19:477–484CrossRefPubMed
7.
Sakai K, Kitagawa Y, Saiki S, Saiki M, Hirose G (2004) Effect of a paraneoplastic cerebellar degeneration-associated neural protein on B-myb promoter activity. Neurobiol Dis 15:529–533CrossRefPubMed
8.
Takanaga H, Mukai H, Shibata H, Toshimori M, Ono Y (1998) PKN interacts with a paraneoplastic cerebellar degeneration-associated antigen, which is a potential transcription factor. Exp Cell Res 241:363–372CrossRefPubMed
9.
Balamurugan K, Luu VD, Kaufmann MR, Hofmann VS, Boysen G, Barth S, Bordoli MR, Stiehl DP, Moch H, Schraml P, Wenger RH, Camenisch G (2009) Onconeuronal cerebellar degeneration-related antigen, Cdr2, is strongly expressed in papillary renal cell carcinoma and leads to attenuated hypoxic response. Oncogene 28:3274–3285CrossRefPubMed
10.
O’Donvan KJ, Diedler J, Couture GC, Fak JJ, Darnell RB (2010) The onconeural antigen cdr2 is a novel APC/C target that acts in mitosis to regulate c-myc target genes in mammalian tumor cells. PLoS ONE 5:e10045CrossRef
11.
Storstein A, Krossnes BK, Vedeler CA (2009) Morphological and immunohistochemical characterization of paraneoplastic cerebellar degeneration associated with Yo antibodies. Acta Neurol Scand 120:64–67CrossRefPubMed
12.
Monstad SE, Storstein A, Dorum A, Knudsen A, Lonning PE, Salvesen HB, Aarseth JH, Vedeler CA (2006) Yo antibodies in ovarian and breast cancer patients detected by a sensitive immunoprecipitation technique. Clin Exp Immunol 144:53–58CrossRefPubMed
13.
Monstad SE, Knudsen A, Salvesen HB, Aarseth JH, Vedeler CA (2009) Onconeural antibodies in sera from patients with various types of tumours. Cancer Immunol Immunother 58:1795–1800CrossRefPubMed
14.
Totland C, Bredholt G, Haugen M, Haukanes BI, Vedeler CA (2010) Antibody to CCDC104 is associated with a paraneoplastic antibody to CDR2 (anti-Yo). Cancer Immunol Immunother 59:231–237CrossRef
15.
Storstein A, Knudsen A, Vedeler CA (2005) Proteasome antibodies in paraneoplastic cerebellar degeneration. J Neuroimmunol 165:172–178CrossRefPubMed
16.
D’Alessandro V, Muscarella LA, la Torre A, Bisceglia M, Parrella P, Scaramuzzi G, Storlazzi CT, Trombetta D, Kok K, De Cata A, Sperandeo M, Zelante L, Carella M, Vendemiale G (2010) Molecular analysis of the HuD gene in neuroendocrine lung cancers. Lung Cancer 67:69–75CrossRefPubMed
17.
King PH (1997) Differential expression of the neuroendocrine genes Hel-N1 and HuD in small-cell lung carcinoma: evidence for down-regulation of HuD in the variant phenotype. Int J Cancer 74:378–382CrossRefPubMed
18.
Dalmau J, Graus F, Cheung NK, Rosenblum MK, Ho A, Canete A, Delattre JY, Thompson SJ, Posner JB (1995) Major histocompatibility proteins, anti-Hu antibodies, and paraneoplastic encephalomyelitis in neuroblastoma and small cell lung cancer. Cancer 75:99–109CrossRefPubMed
19.
de Graaf MT, de Beukelaar JWK, Haasnoot GW, Levering WHBM, Rogemond V, Didelot A, Honnorat J, Gratama JW, Sillewis Smitt PAE (2010) HLA-DQ2+ individuals are susceptible to Hu-Ab associated paraneoplastic neurlogical syndromes. J Neuroimmunol 226:147–149
20.
Tani T, Tanaka K, Idezuka J, Nishizawa M (2008) Regulatory T cells in paraneoplastic neurological syndromes. J Neuroimmunol 196:166–169CrossRefPubMed
Metadata
Title
CDR2 antigen and Yo antibodies
Authors
Cecilie Totland
Nina K. Aarskog
Tilo W. Eichler
Mette Haugen
Jane K. Nøstbakken
Sissel E. Monstad
Helga B. Salvesen
Sverre Mørk
Bjørn I. Haukanes
Christian A. Vedeler
Publication date
01-02-2011
Publisher
Springer-Verlag
Published in
Cancer Immunology, Immunotherapy / Issue 2/2011
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-010-0943-9

Other articles of this Issue 2/2011

Cancer Immunology, Immunotherapy 2/2011 Go to the issue

Original Article

Wild-type and modified gp100 peptide-pulsed dendritic cell vaccination of advanced melanoma patients can lead to long-term clinical responses independent of the peptide used

Review

Experimental immunotherapy for malignant glioma: lessons from two decades of research in the GL261 model

Original Article

A phase II study of the cancer vaccine TG4010 alone and in combination with cytokines in patients with metastatic renal clear-cell carcinoma: clinical and immunological findings

Original Article

Primed tumor-reactive multifunctional CD62L+ human CD8+ T cells for immunotherapy

Short Communication

CD8 Co-receptor promotes susceptibility of CD8+ T cells to transforming growth factor-β (TGF-β)-mediated suppression

Original Article

Analysis of circulating regulatory T cells in patients with metastatic prostate cancer pre- versus post-vaccination
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits